Could spacing out prostate cancer drug doses boost quality of life without shortening survival?
NCT ID NCT07200830
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times
Summary
This phase 3 trial tests whether giving the prostate cancer drug lutetium-177 PSMA less often, based on how the cancer responds, can improve quality of life without shortening survival. The study involves 1,524 men with advanced, hormone-resistant prostate cancer that has spread. After two initial doses, some patients will receive the next doses only when their cancer shows signs of activity, instead of on a fixed schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.